Drugs / Army Liposome Formulation
Army Liposome Formulation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05769569 | Sep 2023 → Jul 2025 | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Army Liposome Formulation | “ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21.” NCT05769569 ↗ |
| Known as | ALF | “ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21.” NCT05769569 ↗ |
| Known as | ALFQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05769569 ↗ |
| Modality | Other / unclassified | “liposomal adjuvant” NCT05769569 ↗ |